医学
卡铂
剜除术
外科
视网膜母细胞瘤
依托泊苷
长春新碱
化疗
化疗方案
养生
临床终点
随机对照试验
内科学
顺铂
环磷酰胺
基因
化学
生物化学
作者
Huijing Ye,Kang Xue,Ping Zhang,Rongxin Chen,Xiaowen Zhai,Li Ling,Wei Ma,Lijuan Tang,Hongsheng Wang,Yuxiang Mao,Siming Ai,Yingwen Bi,Qing Liu,Yusha Zou,Qian Jiang,Huasheng Yang
出处
期刊:JAMA
[American Medical Association]
日期:2024-10-21
标识
DOI:10.1001/jama.2024.19981
摘要
Importance Adjuvant therapy is an important and effective treatment for retinoblastoma. However, there is a lack of head-to-head clinical trials comparing 3 vs 6 cycles of CEV chemotherapy (carboplatin, etoposide, and vincristine) for enucleated unilateral retinoblastoma with high-risk pathological features. Objective To assess whether 3 cycles of CEV chemotherapy is noninferior to 6 cycles for enucleated unilateral retinoblastoma with high-risk pathological features. Design, Setting, and Participants This double-center, randomized, open-label, noninferiority trial was conducted at 2 premier eye centers in China and included 187 patients who had undergone enucleation for unilateral retinoblastoma with high-risk pathological features (massive choroidal infiltration, retrolaminar optic nerve invasion, or scleral infiltration) between August 2013 and March 2024. The final date of follow-up was March 21, 2024. Interventions Patients were randomly assigned to receive either 3 (n = 94) or 6 (n = 93) cycles of CEV chemotherapy regimen after enucleation. Main Outcomes and Measures The primary end point was disease-free survival, with a noninferiority margin of 12%. Secondary end points encompassed overall survival, safety, economic burden, and the quality of life of children. Results All 187 patients (median [IQR] age, 25.0 [20.0-37.0] months; 83 [44.4%] female) completed the trial. Median (IQR) follow-up was 79.0 (65.5-102.5) months. Five-year disease-free survival was 90.4% for the 3-cycle group vs 89.2% for the 6-cycle group (difference, 1.2% [95% CI, −7.5% to 9.8%]), which met the noninferiority criterion ( P = .003 for noninferiority). The 6-cycle group experienced a higher frequency of adverse events, greater reduction in quality of life scores, and increased costs compared with the 3-cycle group. Conclusions and Relevance Among patients with unilateral pathologic high-risk retinoblastoma, 3 cycles of CEV chemotherapy resulted in 5-year disease-free survival that was noninferior to 6 cycles of CEV chemotherapy. Trial Registration ClinicalTrials.gov Identifier: NCT01906814
科研通智能强力驱动
Strongly Powered by AbleSci AI